Tuberous Sclerosis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Tuberous Sclerosis – Drugs In Development, 2024 report and make more profitable business decisions.
Tuberous sclerosis complex (TSC), an autosomal dominant genetic disorder, impacts multiple systems with an elevated tendency for hamartoma formation. Mutations in TSC1 and TSC2 genes, governing proteins that regulate cell division and growth, underlie the disorder. Typically identified in childhood or infancy, TSC manifests with developmental delays, skin issues, and seizures. Diagnosis relies on clinical criteria, supplemented by genetic testing, which detects mutations in TSC1 and TSC2 genes in 75% to 95% of affected individuals. Current screening tests focus on identifying pathogenic mutations causing TSC1 or TSC2 protein inactivation, leading to the loss of mTOR inhibition, a key factor in TSC pathogenesis.
The Tuberous Sclerosis drugs in development market research report provide comprehensive information on the therapeutics under development for Tuberous Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tuberous Sclerosis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Tuberous Sclerosis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 14 molecules, with 14 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Tuberous Sclerosis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Tuberous Sclerosis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Tuberous Sclerosis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aeovian Pharmaceuticals IncAnavex Life Sciences Corp
BioSputnik LLC
BridgeBio Pharma Inc
Jazz Pharmaceuticals Plc
Longboard Pharmaceuticals Inc
Marinus Pharmaceuticals Inc
Nobelpharma Co Ltd
Noema Pharma AG
Ovid Therapeutics Inc
Quiver Bioscience Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Tuberous Sclerosis reports